Epigenetic Therapies and Technologies: World Market Prospects 2011-2021
NEW YORK, Nov. 28, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Epigenetic Therapies and Technologies: World Market Prospects 2011-2021
http://www.reportlinker.com/p0692157/Epigenetic-Therapies-and-Technologies-World-Market-Prospects-2011-2021.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy
What are the prospects for epigenetic products and technologies? Visiongain's report shows you potential revenues to 2021, discussing trends and opportunities.
Where is the epigenetics market heading? Find revenue predictions for epigenetic applications at total world, submarket, product and national levels to 2021. Through our research and analyses we aim to save you time and help in your decisions.
You can see how existing epigenetic therapies will perform to 2021. What opportunities exist in cancer treatment and other areas? Our report shows you commercial potential in epigenetic technologies.
Interest in epigenetic therapies is gathering pace, with around 15 products in clinical trials and many more in pre-clinical development. What epigenetic R&D projects will have the greatest impact?
Our report gives you coverage of HDAC inhibitors, DNMT inhibitors, histone methyl transferase inhibitors and other epigenetic pathways. There is a strong R&D pipeline.
Epigenetic modifications can also act as biomarkers; these have led to the development of clinical diagnostic and prognostic tests. You can see how technologies are developing.
This study discusses Celgene, Eisai, Merck & Co., GSK, Roche, Epigenomics, Exact Sciences, MDxHealth and many other companies. Receive coverage of pharma, diagnostics and technology companies for epigenetics.
Discover data, analysis and opinion to benefit your research, calculations, meetings and presentations. You can find answers now in our work.
Revenue forecasts, market shares, developmental trends, discussions and interviews
In our report you find revenue forecasts, growth rates, market shares, qualitative analyses (incl. SWOT and STEP), an R&D review and opinions from our survey. You receive 95 tables and charts and two research interviews.
Advantages of Epigenetic Therapies and Technologies: World Market Prospects 2011-2021 for your work
Our report gives you the following advantages in particular:
• Find revenue predictions to 2021 for the overall world market and submarkets - epigenetic therapies, epigenetic technologies and epigenetic diagnostics
• Discover revenue forecasts to 2021 for marketed epigenetic treatments - Vidaza, Dacogen, Zolinza and Istodax - assessing commercial potentials
• See overall epigenetic revenue forecasts to 2021 for the US, Japan, the UK,Germany, France, Italy and Spain
• Assess the leading companies, discovering their activities and outlooks
• Review R&D for epigenetic agents, seeing pipeline trends
• Investigate competition and opportunities influencing the industry and market
• See what will stimulate and restrain the industry and market from 2011
• View opinions from our survey, receiving detailed interview transcripts.
There, you find a distinctive mix of quantitative and qualitative analyses with independent predictions. We tackle crucial questions on epigenetic medicine, helping you to stay ahead.
Gain industry and market analysis now for epigenetic medicine
Our report is for everybody needing industry and market analysis for epigenetic products and technologies. Find trends and answers. Avoid missing out - please order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Table of Contents
1. Executive Summary
1.1 Epigenetic Therapies and Technologies: World Market Review
1.2 Chapter Breakdown
1.3 Research and Analysis Methods
2. Introduction to Epigenetics in Medicine
2.1 Definition of Epigenetics
2.1.1 Epigenetic Mechanisms
2.2 Epigenetics and Disease
2.2.1 Epigenetics and Cancer
2.2.2 Epigenetics and Other Diseases
2.3 Epigenetic Therapies
2.4 Epigenetics in Drug Discovery and Development
2.4.1 Bisulphite Screening
2.4.2 Chromatin Immunoprecipitation (ChIP)
2.5 Epigenetics and Diagnosis
3. The Epigenetic Therapies and Technologies Market 2011-2021
3.1 The Epigenetic Therapies and Technologies Market 2010
3.2 The Epigenetic Therapies and Technologies Market: Overall Revenue Forecast 2011-2021
3.3 Epigenetic Therapies Submarket 2010
3.3.1 Epigenetic Therapies Submarket: Revenue Forecast 2011-2021
3.3.2 DNMT Inhibitors
3.3.2.1 Myelodysplastic Syndromes (MDS)
3.3.3 Vidaza
3.3.3.1 Vidaza: Revenue Forecast 2011-2021
3.3.4 Dacogen
3.3.4.1 Dacogen: Revenue Forecast 2011-2021
3.3.5 HDAC Inhibitors
3.3.5.1 Cutaneous T Cell Lymphoma (CTCL)
3.3.6 Zolinza
3.3.6.1 Zolinza: Revenue Forecast 2011-2021
3.3.7 Istodax
3.3.7.1 Peripheral T Cell Lymphoma (PTCL)
3.3.7.2 Istodax: Revenue Forecast 2011-2021
3.4 Epigenetic Diagnostics Submarket 2010
3.4.1 Epigenetic Diagnostics Submarket: Revenue Forecast 2011-2021
3.4.1.1 Colorectal Cancer
3.4.1.2 Breast Cancer
3.4.1.3 Prostate Cancer
3.4.1.4 Other Cancers
3.5 Epigenetic Technologies Submarket 2010
3.5.1 Epigenetic Technologies Submarket: Revenue Forecast 2011-2021
3.5.1.1 DNA Methylation Analysis
3.5.1.2 Histone Modification Analysis
3.5.1.3 Next-Generation Sequencing Technologies
4. Leading National Epigenetic Markets 2011-2021
4.1 Leading National Markets: Revenue Forecasts 2011-2021
4.2 The US: Revenues 2011-2021
4.3 The European Market: Revenues 2011-2021
4.4 Japan: Revenues 2011-2021
4.5 Epigenetics in Emerging Markets
5. Epigenetic Therapy R&D Pipeline in 2011
5.1 HDAC Inhibitors
5.1.1 PXD-101 (Belinostat Topotarget/Spectrum Pharmaceuticals)
5.1.2 LBH589 (Panobinostat, Novartis)
5.1.3 Entinostat (Syndax Pharmaceuticals)
5.1.4 4SC-201 (Resminostat, 4SC)
5.1.5 MGCD-0103 (Mocetinostat, MethylGene)
5.1.6 SB939 (S*BIO)
5.1.7 ACY-1215 (Acetylon Pharmaceuticals)
5.1.8 EVP-0334 (EnVivo Pharmaceuticals/MethylGene)
5.1.9 CHR-2845 (Tefinostat, Chroma Therapeutics)
5.1.10 CXD101 (Celleron Therapeutics)
5.1.11 RG2833 (Repligen)
5.1.12 PCI-24781 (Pharmacyclics/Les Laboratoires Servier)
5.1.13 JNJ26481585 (Centocor Research & Development)
5.1.14 Valproic Acid
5.2 DNMT Inhibitors
5.2.1 SGI-110 (Astex Pharmaceuticals)
5.2.2 CP-4200 (Clavis Pharma)
5.3 Histone Methyltransferase Inhibitors
5.3.1 DOT1L Inhibitors
5.3.2 EZH2 Inhibitors
5.4 Other Epigenetic Pathways
6. Leading Companies in the Epigenetics Market in 2011
6.1 Epigenetic Therapy Companies
6.1.1 Celgene
6.1.2 Eisai
6.1.3 Merck & Co.
6.1.4 Clinical-Stage Companies
6.1.4.1 4SC
6.1.4.2 Astex Pharmaceuticals
6.1.4.3 Chroma Therapeutics
6.1.4.4 MethylGene
6.1.4.5 Spectrum Pharmaceuticals
6.1.4.6 Syndax Pharmaceuticals
6.1.5 Pre-Clinical Stage Companies
6.1.5.1 CellCentric
6.1.5.2 Constellation Pharmaceuticals
6.1.5.3 EpiTherapeutics
6.1.5.4 Epizyme
6.1.5.5 IkerChem
6.2 Epigenetic Diagnostics Companies
6.2.1 Epigenomics
6.2.2 Exact Sciences
6.2.3 MDxHealth
6.2.4 Orion Genomics
6.2.5 PrognosDx Health
6.3 Epigenetic Technology Companies
6.3.1 Active Motif
6.3.2 Cellzome
6.3.3 Diagenode
6.3.4 EMD Millipore
6.3.5 Epigentek
6.3.6 Life Technologies
6.3.7 Roche
7. Epigenetic Therapies and Technologies: Industry Trends 2011-2021
7.1 Strengths and Weaknesses in the Epigenetic Therapies and Technologies Market in 2010
7.2 Opportunities and Threats in the Epigenetic Therapies and Technologies Market 2011-2021
7.2.1 Big Pharma Entering the Industry
7.2.1.1 GSK
7.2.2 Business Models for Epigenetics
7.2.3 A Rapidly Expanding Pipeline
7.2.4 An Explanation for - and a Solution to - Drug Resistance?
7.2.5 Epigenetics and Stem Cells
7.2.5.1 Induced Pluripotent Stem Cells (iPSCs)
7.2.6 A Burgeoning Field of Research
7.2.6.1 Costs of Research
7.2.7 Non-Commercial Support for Research
7.2.7.1 Global Collaboration
7.2.7.2 Funding Epigenetic Research in the EU
7.2.8 The Ethics of Epigenetics
7.3 The Impact of the Environment
7.3.1 An Ageing Global Population
7.4 Therapeutic Potential Beyond Cancer
7.4.1 Autoimmune Diseases
7.4.1.1 Rheumatoid Arthritis
7.4.1.2 Lupus
7.4.2 Neurodegenerative Diseases
7.4.2.1 Alzheimer's Disease
7.4.3 Psychiatric Disorders
7.4.4 Diabetes and Obesity
8. Research Interviews
8.1 Dr Anthony Brown, Scientific Director, CellCentric
8.1.1 Collaboration in Epigenetic Research and Drug Development
8.1.1.1 Collaboration in the EU
8.1.2 Potential for New Classes of Epigenetic Enzyme
8.1.3 Specificity in HDAC Inhibitors
8.1.4 Epigenetics as Combination Therapies
8.1.5 The Context of Epigenetic Modifications
8.1.6 Challenges in Epigenetic Drug Development
8.2 Dr Martin Bonde, CEO, EpiTherapeutics
8.2.1 Potential for Histone Methyltransferase Inhibitors
8.2.2 Future of Epigenetics Research
8.2.3 Challenges in Developing Epigenetic Therapies
8.2.4 Benefits of University Spin-Outs
9. Conclusions from Our Study
9.1 Growth in the Epigenetic Therapies and Technologies Market 2011-2021
9.1.1 Diagnostics Set for Rapid Growth
9.1.2 Continued Dominance of Developed Markets
9.2 Global Collaboration
9.3 Applications in Cancer Will Remain Important in this Field
List of Tables
Table 1.1 Currency Exchange Rates, 2010
Table 3.1 Epigenetic Therapies and Technologies Market by Sector, 2010
Table 3.2 Epigenetic Therapies and Technologies Market: Overall Market and Revenue Forecasts by Sector, 2010-2021
Table 3.3 Epigenetic Therapies and Technologies: Submarket Shares, 2010-2021
Table 3.4 Epigenetic Therapies Submarket: Revenues, 2010
Table 3.5 US Epigenetic Therapy Patent Expiries, 2011-2021
Table 3.6 Epigenetic Therapy Submarket: Drivers and Restraints, 2011-2021
Table 3.7 Earliest Market Entries for Pipeline Epigenetic Therapies, 2013-2016
Table 3.8 Epigenetic Therapies Submarket: Revenue Forecast, 2010-2021
Table 3.9 Vidaza: Revenue, 2007-2010
Table 3.10 Vidaza: Drivers and Restraints, 2011-2021
Table 3.11 Vidaza: Ongoing Clinical Trials, 2011
Table 3.12 Vidaza: Revenue Forecast, 2010-2021
Table 3.13 Dacogen: Royalties, 2008-2010
Table 3.14 Dacogen: Drivers and Restraints, 2011-2021
Table 3.15 Dacogen: Ongoing Clinical Trials, 2011
Table 3.16 Dacogen: Revenue Forecast, 2010-2021
Table 3.17 Zolinza: Ongoing Clinical Trials, 2011
Table 3.18 Zolinza: Drivers and Restraints, 2011-2021
Table 3.19 Zolinza: Revenue Forecast, 2010-2021
Table 3.20 Istodax: Drivers and Restraints, 2011-2021
Table 3.21 Istodax: Revenue Forecast, 2010-2021
Table 3.22 Istodax: Ongoing Clinical Trials, 2011
Table 3.23 Selected Epigenetic Clinical Diagnostics Marketed and in Development, 2011
Table 3.24 Selected Epigenetic Companion Diagnostics Marketed and in Development, 2011
Table 3.25 Epigenetic Diagnostics Submarket: Drivers and Restraints, 2011-2021
Table 3.26 Epigenetic Diagnostics Submarket: Revenue Forecast, 2010-2021
Table 3.27 Five-Year Survival Rates for Nine Cancers in the UK, 2009
Table 3.28 Selected Producers of ChIP Assay Kits for Epigenetic Research, 2011
Table 3.29 Selected Producers of ChIP-Seq Kits for Epigenetic Research, 2011
Table 3.30 Epigenetic Technologies Submarket: Drivers and Restraints, 2011-2021
Table 3.31 Epigenetic Technologies Submarket: Revenue Forecast, 2010-2021
Table 3.32 Selected Producers of Single-Molecule Sequencing Technologies, 2011
Table 4.1 Epigenetic Therapies and Technologies Market by Region, 2010
Table 4.2 Epigenetic Clinical Trials by Region, 2011
Table 4.3 Epigenetic Therapies and Technologies Market: Revenue Forecasts by Region, 2010-2021
Table 4.4 Prevalence of MDS and CTCL in Major Developed Markets, 2011
Table 4.5 European Epigenetic Therapies and Technologies Market by Country, 2010
Table 4.6 European Epigenetic Therapies and Technologies Market: Revenue Forecasts by Country, 2010-2021
Table 4.7 Epigenetic Therapy Approvals in the US and Japan, 2004-2011
Table 5.1 Selected HDAC Inhibitor Pipeline Candidates, 2011
Table 5.2 Ongoing Clinical Trials for PXD-101 (Belinostat), 2011
Table 6.1 CellCentric's Research Institution Affiliations, 2011
Table 6.2 IkerChem: Epigenetic Therapy Pipeline, 2011
Table 6.3 Epigenomics: Colorectal Diagnostics Licences, 2011
Table 6.4 Epigenomics: Licensing and Product Revenue, H1 2010-2011
Table 6.5 MDxHealth: Prognostic Test Pipeline, 2011
Table 7.1 Epigenetic Therapies and Technologies Market: Strength and Weaknesses, 2011
Table 7.2 Opportunities and Threats Facing the Epigenetic Therapies and Technologies Market, 2011
Table 7.3 Selected University Spin-Outs in the Epigenetics Industry, 1997-2008
Table 7.4 Average Cost of Sequencing the Human Genome, 2000-2011
Table 7.5 Epigenomics Roadmap Funded Projects, 2008-2011
Table 7.6 SGC Epigenetics Partners, 2011
Table 7.7 IHEC Members, 2011
Table 7.8 Ageing Global Population: Statistics, 2009, 2025 and 2050
Table 7.9 Prevalence of Serious Mental Illness in the US, 2011
Table 9.1 Epigenetic Therapies and Technologies Market: Revenues by Sector, 2010, 2015 and 2021
Table 9.2 Epigenetic Therapies and Technologies Market: Revenues by Region, 2010, 2015 and 2021
List of Figures
Figure 2.1 Chromatin Immunoprecipitation (ChIP) Process
Figure 3.1 Epigenetic Therapies and Technologies Market by Sector, 2010
Figure 3.2 Epigenetic Therapies and Technologies Market: Overall Market and Revenue Forecasts by Sector, 2010-2021
Figure 3.3 Epigenetic Therapies and Technologies Market by Sector, 2015
Figure 3.4 Epigenetic Therapies and Technologies Market by Sector, 2021
Figure 3.5 Epigenetic Therapies Submarket: Revenues, 2010
Figure 3.6 Epigenetic Therapies Submarket by Enzyme Class, 2010
Figure 3.7 Epigenetic Therapies Submarket: Revenue Forecast, 2010-2021
Figure 3.8 MDS Treatment Options, 2011
Figure 3.9 Vidaza: Revenue, 2007-2010
Figure 3.10 Vidaza: Revenue Forecast, 2010-2021
Figure 3.11 Vidaza and Dacogen Chemical Structures
Figure 3.12 Dacogen: Royalties, 2008-2010
Figure 3.13 Dacogen: Revenue Forecast, 2010-2021
Figure 3.14 Stages of Cutaneous T Cell Lymphoma
Figure 3.15 Zolinza: Revenue Forecast, 2010-2021
Figure 3.16 Istodax: Revenue Forecast, 2010-2021
Figure 3.17 Epigenetic Diagnostics Submarket: Revenue Forecast, 2010-2021
Figure 3.18 Five-Year Survival Rates of Nine Cancers in the UK, 2009
Figure 3.19 Epigenetic Technologies Submarket: Revenue Forecast, 2010-2021
Figure 4.1 Epigenetic Therapies and Technologies Market by Region, 2010
Figure 4.2 Epigenetic Clinical Trials by Region, 2011
Figure 4.3 Epigenetic Therapies and Technologies Market by Region, 2015
Figure 4.4 Epigenetic Therapies and Technologies Market by Region, 2021
Figure 4.5 US Epigenetic Therapies and Technologies Market: Revenue Forecast, 2010-2021
Figure 4.6 Prevalence of MDS and CTCL in Major Developed Markets, 2011
Figure 4.7 European Epigenetic Therapies and Technologies Market by Country, 2010
Figure 4.8 European Epigenetic Therapies and Technologies Market: Revenue Forecast, 2010-2021
Figure 4.9 European Epigenetic Therapies and Technologies Market: Revenue Forecasts by Country, 2010-2021
Figure 4.10 Japanese Epigenetic Therapies and Technologies Market: Revenue Forecast, 2010-2021
Figure 6.1 The Founding of Epigenetic Companies, 1987-2008
Figure 6.2 Epigenomics: Licensing and Product Revenue, H1 2010-2011
Figure 7.1 Average Cost of Sequencing the Human Genome, 2000-2011
Figure 7.2 Ageing Global Population: Statistics, 2009, 2025 and 2050
Figure 7.3 Prevalence of Serious Mental Illness in the US, 2011
Figure 9.1 Epigenetic Therapies and Technologies Market: Revenues by Sector, 2010, 2015 and 2021
Figure 9.2 Epigenetic Therapies and Technologies Market: Revenues by Region, 2010, 2015 and 2021
Companies Listed
454 Life Sciences (now part of Roche)
4SC
Abbott Laboratories
Abingworth
Acetylon Pharmaceuticals
Active Motif
Agilent Technologies
Allos Therapeutics
Amgen
Amgen Ventures
ARUP Laboratories [US]
Astellas Venture Management
Astex Pharmaceuticals (formerly SuperGen)
Astex Therapeutics (now part of Astex Pharmaceuticals)
AstraZeneca
Aton Pharma (now part of Merck & Co)
Bay City Capital
Bayer
Bayside Health Association
BGI (formerly Beijing Genomics Institute)
Brabraham Institute [UK]
Canadian Institute for Health Research (CIHR)
CanAm Bioresearch
Cancer Research UK
Cancer Research Ventures
Cancer Science Institute of Singapore (CSI Singapore)
Case Comprehensive Cancer Center [US]
Celgene
Celgene Institute of Translational Research Europe (CITRE)
CellCentric
Celleron Therapeutics
Cellzome
Centocor Research & Development
Centre for Addiction and Mental Health (CAMH) [Canada]
Centre for Genome Science [South Korea]
Centre for Genomic Regulation [Spain]
Centre National de Génotypage [France]
Centre National de la Recherche Scientifique (CNRS) [France]
Chroma Therapeutics
Clavis Pharma
Constellation Pharmaceuticals
Dana-Farber Cancer Institute [US]
Diagenode
Duke University [US]
Edinburgh University
Eisai
Eli Lilly
EMA Committee for Medicinal Products for Human Use (CHMP)
EMD Millipore (part of Merck KGaA)
Emory University [US]
EnVivo Pharmaceuticals
Epigenetics Dream Team (Stand Up To Cancer) [US]
Epigenome/EpiGeneSys Networks of Excellence [Europe]
Epigenomics
Epigentek
EpiTherapeutics
Epizyme
European Commission
European Institute of Oncology (IEO)
European Medicines Agency (EMA)
Exact Sciences
Federal Ministry of Education and Research (BMBF) [Germany]
Flagship Biosciences
Food and Drug Administration (FDA) [US]
Friedreich's Ataxia Research Alliance (FARA) [US]
Genentech (now part of Roche)
Genpathway (now part of Active Motif)
GlaxoSmithKline (GSK)
Gloucester Pharmaceuticals (now part of Celgene)
Go FAR (Friedreich's Ataxia Research) [Italy]
Gynecolgic Oncology Associates [US]
Hackensack University Medical Center [US]
Hannover Medical School
Harvard University
Helicos BioSciences
Human Epigenome Consortium
IkerChem
Indiana University
International Human Epigenome Consortium (IHEC)
Janssen-Cilag (subsidiary of J&J)
Japan Science and Technology Agency (JST)
Japanese Society for Epigenetics
John Hopkins University
Johnson & Johnson (J&J)
King's College London
Les Laboratoires Servier (Servier)
Leukemia and Lymphoma Society [US]
Life Technologies (formerly Invitrogen and Applied Biosystems)
Louis Pasteur University of Strasbourg
Lundbeckfond Ventures
M.D. Anderson Cancer Centre [US]
Macmillan Cancer Support [UK]
Massachusetts General Hospital
Mayo Clinic [US]
McGill University [Canada]
MDxHealth (formerly OncoMethylome)
Merck & Co.
Merck KGaA
Merck Serono Ventures
MethylGene
MGI Pharma (now part of Eisai)
Ministry of Health, Labor and Welfare (MHLW) [Japan]
Mount Sinai Medical Center [US]
Multiple Myeloma Research Foundation [US]
Muscular Dystrophy Association (MDA) [US]
National Ataxia Foundation (NAF) [US]
National Cancer Center [South Korea]
National Cancer Institute (NCI) [US]
National Cancer Institute of Canada (now Canadian Cancer Society Research Institute)
National Health Service (NHS) [UK]
National Institute for Health and Clinical Excellence (NICE) [UK]
National Institute for Mental Health (NIMH) [US]
National Institutes of Health Chemical Genomics Center (NCGC) [US]
National University Cancer Institute Singapore (NCIS)
Nomura Phase4
Novartis
NovioGendix
Novo Nordisk
Novo Seeds
Nycomed
Ontario Institute for Cancer Research
Onyx Pharmaceuticals
Orion Genomics
Pacific Biosciences
Peter MacCallum Cancer Centre [Australia]
Pfizer
Pharmacyclics
Pharmion (now part of Celgene)
Predictive Biosciences
PrognosDx Health
Qiagen
Quest Diagnostics
Repligen
Roche
Roche NimbleGen (formerly NimbleGen Systems)
S*BIO
Scottish Medicines Consortium
Seed Capital
Sigma-Aldrich
Simmons Cancer Center [US]
Spectrum Pharmaceuticals
Stanford University
Structural Genomics Consortium (SGC)
Syndax Pharmaceuticals
Sysmex
Taiho Pharmaceutical
Takeda
The Automation Partnership (now TAP Biosystems)
Thermo Scientific
Thomas Jefferson University [US]
Topotarget
Umeå University [Sweden]
United Nations (UN)
University of Birmingham [UK]
University of California, Los Angeles (UCLA)
University of Cambridge
University of Colorado
University of Copenhagen
University of Kansas
University of Maryland
University of Miami
University of Nottingham
University of Oxford
University of Southern California
University of the Basque Country
University of Wuerzburg [Germany]
USB
Vernalis
VisiGen (now part of Life Technologies)
Warnex
Wellcome Trust [UK]
Wistar Institute [US]
World Health Organization (WHO)
Yakult Honsha
To order this report:
Therapy Industry: Epigenetic Therapies and Technologies: World Market Prospects 2011-2021
Check our Industry Analysis and Insights
CONTACT
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article